Therapeutic angiogenesis is a promising new concept for the treatment of myocardial and peripheral ischaemia. Members of the VEGF (vascular endothelial growth factor) family are among the most powerful modulators of angiogenesis. They regulate vascular growth and maintenance during embryogenesis and in adults. The present review summarizes the current status of therapeutic angiogenesis using VEGF, with special reference to preclinical studies.
Introduction
Therapeutic angiogenesis involves stimulation of angiogenesis, arteriogenesis and lymphangiogenesis [1] . Angiogenesis means sprouting, bridging, intussusception or enlargement of capillaries, whereas arteriogenesis means growth and enlargement of pre-existing muscular collateral vessels. Lymphangiogenesis involves generation of new lymphatic vessels from the pre-existing ones [2] . Strategies have also been presented for the use of endothelial progenitor cells and stem cells for therapeutic angiogenesis, which could be augmented with VEGFs (vascular endothelial growth factors) or other growth factors. However, progenitor cells and stem cells will not be discussed in the present review but the reader is referred to a recent review covering these areas [3] .
VEGF and angiogenesis
VEGF is one of the most effective angiogenic growth factors that can lead to the formation of new vasculature by its effects on ECs (endothelial cells) and by stimulating the expression of other growth factors [4] . Conversely, at least some other growth factors, such as placental growth factor, hepatocyte growth factor and fibroblast growth factor-4, induce new blood vessels at least in part via up-regulation of VEGF [5, 6] . In ischaemic tissues, VEGF needs to form a gradient, originating from ischaemic areas, towards which ECs and neovessels migrate [7, 8] . Tip cells at the leading edge of the capillary sprouts can recognize VEGF concentrations and direct the angiogenic process to the ischaemic areas [9] . VEGF has several isoforms with different binding affinities to the extracellular matrix that constitute VEGF gradients in tissues [7, 10] .
It is important to recognize that, at least in muscles, the angiogenic response is dependent on the status of blood flow [11] . In preclinical animal models, the main response to VEGFs in non-ischaemic muscles is primarily enlargement of capillaries, small arterioles and veins instead of massive sprouting angiogenesis [11, 12] . On the other hand, sprouting angiogenesis, and even the formation of non-natural large capillary structures, are seen in ischaemic muscles with greatly reduced blood flow [11] . Thus blood flow modifies vascular responses to pro-angiogenic therapy. Therefore, in therapeutic applications, it might be useful to combine VEGF gene therapy with simultaneous revascularization procedures.
In order to improve quantitative blood flow in skeletal muscles and myocardium arteriogenesis of larger blood vessels is required [13] . Since arteriogenesis does not usually originate from ischaemic areas but from non-ischaemic tissues, this implies that therapeutic factors need to be effective also in the non-ischaemic muscles, otherwise they may not work in the human situation. It seems pertinent to conclude that a reduced resistance in the peripheral small arterioles together with an increased volume of the capillary bed, veins and lymphatic vessels will bring more blood flow into the muscles. Increased blood flow will then enlarge proximal arterioles and improve the overall situation [11] .
Thus it is evident that the haemodynamic status of the muscle, generation of appropriate VEGF gradients and restoration of the blood flow are central to successful angiogenic therapy. In wound healing, the outcome of angiogenesis is regression of all new vessels that are not needed. Only those vessels that are vital for tissue function will persist. This natural phenomenon could also explain some findings, suggesting that exercise may strengthen angiogenic therapy.
Bone marrow-derived mononuclear and inflammatory cells found in angiogenic tissues play important roles in angiogenesis [3] . However, previous reports suggest that these cells do not directly incorporate into the growing vasculature but stimulate the angiogenic process mainly by secreting cytokines and growth factors [14, 15] . VEGF seems to play an important role in the homing of these cells in angiogenic tissues [16] .
Lessons from preclinical animal models
When transducing skeletal muscle with adenoviruses expressing VEGFs, transduced cells are not only myocytes but also fibroblasts located around muscle fibres [6] . Therefore a secreted factor is needed for a therapeutic effect on muscle capillaries and other vessels. Many preclinical studies have been performed in small animal models where transduction is much more efficient than can be achieved in larger animals or human [1] . Whereas vectors may be effective in small mouse muscles, they may not effectively spread over larger muscle volumes in humans [1, 17] . Also, doses used in small animals have been very high. For example, 10 11 viral particles in a mouse would correspond to 3×10 14 viral particles in a human [18] . A 28G needle causes a ∼500 μm wide needle track in mouse muscles where damaged myocytes and inflammatory cells will become a confounding source of cytokines and growth factors. This needle track is ∼20% of the total width of the left ventricle in mouse heart, but only 1/200 of the width of the human myocardium [18] . Gene therapy results from small animal models are easily overinterpreted regarding their applicability to the human clinical situation. It is obviously easier to transduce the entire muscle in the mouse than human muscle masses hundreds of times larger. Therefore further development in the transduction efficiency in humans is needed before we can expect better clinical results.
Some vascular growth factors, such as VEGF-B, may have tissue-specific effects [19] . Thus new treatment approaches should be tested in the same tissues where the final treatment is directed. Angiogenesis in the human myocardium cannot be fully predicted by studies performed in the chicken allantoic membrane and avascular cornea models.
Dose finding is another area that has not always been done correctly. Dose dependency of the anticipated biological effect should be established in preclinical and clinical studies. Also, a maximal tolerated dose should be identified. If these parameters have not been clarified before phase III trials, it is unlikely that the treatments will produce positive results in humans [17] .
Additionally, VEGF effects are strongly concentration dependent [20] . At a low concentration, VEGF is mostly vasculoprotective due to increased production of NO and prostacyclin [21] . At a higher concentration, it has angiogenic effects [11] , whereas at a still higher dose, it causes pathological angiogenesis and potential haemangioma formation [22] . Since diffusion of the factors is affected by binding to the extracellular matrix and some VEGFs are activated by proteolytic cleavage, the final biological effects may vary in different target tissues.
After reaching the target cells, transduction efficiency is a key parameter since even the best vectors currently available can only transduce approx. 5-10% of the target cells in humans in vivo [23, 24] , which is in sharp contrast with most results obtained from preclinical small animal models. Successful transduction and gene expression involves several steps: binding to vector receptors, uptake of the vector, escape from lysosomes, transport to the nucleus and transcription and translation into mRNA and protein. At the moment, these points are still the Achilles heel of in vivo angiogenic gene therapy.
However, it is very encouraging that adenoviral gene transfer of the members of the VEGF family into ischaemic skeletal muscles in rabbits has improved both the blood flow and metabolic status of the muscles as measured by magnetic resonance spectroscopy [25] . When aerobic capacity and exercise tolerance were measured in rabbit ischaemic muscles, gene transfer significantly improved aerobic capacity and ATP levels as compared with the controls. Also, it appears that a single growth factor gene transfer with an optimized dose of VEGF seems to be sufficient, and very little additional benefit can be achieved with a combination gene therapy using adenoviruses expressing VEGF and PDGF-B (platelet-derived growth factor-B) [26] .
Conclusions
Depending on haemodynamics, VEGF gene therapy has multiple effects in target muscles: under normal blood flow the most prominent effect is dilatation of the existing capillaries, whereas in reduced flow situations sprouting angiogenesis is more prominent. For clinical trials, optimization of the dose and more efficient gene delivery methods are needed, as well as demonstration of the gene transfer efficiency and kinetics of the production of the therapeutic protein. Some tissue-specific properties of the members of the VEGF family, such as VEGF-B for myocardium, may also be utilized in future trials.
